Eli Lilly & Co. (LLY) Announces Presentation of Baricitinib Phase 3 Data in RA, Other Baricitinib at Upcoming Meeting
Tweet Send to a Friend
Eli Lilly & Co. (NYSE: LLY) announced that new post-hoc analyses of pooled efficacy and safety data from baricitinib phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
